Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
GH Research PLC reported financial results for Q2 2026, highlighting successful completion of Phase 1 trials and FDA alignment on CMC and device plans for their Phase 3 pivotal program targeting treatment-resistant depression (TRD). The company strengthened its US and EU patent portfolio for mebufotenin therapies, published positive Phase 2a postpa…
Lee Enterprises, a digital-first local news and advertising platform, announced strong preliminary Q3 fiscal 2026 results, including $5 million net income and a 23% year-over-year increase in Adjusted EBITDA. Digital revenue now constitutes 57% of total revenue, reflecting successful digital transformation. The company increased its fiscal 2026 Adj…
Tilray Brands, Inc. announced the launch of the Mollo Lite Blackberry Lemon Seltzers 4-Pack, introducing its first light THC beverage multi-pack in Canada. This low-dose, sessionable cannabis beverage format targets adult consumers seeking approachable potency with refreshing flavor and convenient multi-pack options. The product enhances Tilray's l…
Gogo Inc., a leading provider of broadband connectivity solutions for business and military aviation markets, announced Q2 2026 results with total revenue of $222.8 million, a 1% decrease year-over-year. Military/government service revenue grew 40% year-over-year and 20% sequentially, marking a record quarter. Net loss was $2.0 million with adjuste…
Harrow, Inc. announced the acquisition of TYRVAYA®, a novel nasal spray treatment for dry eye disease, from Viatris Inc., aiming to enhance its ophthalmic product portfolio. TYRVAYA offers an alternative to eye drops with a unique delivery method and complements Harrow's existing products, expanding treatment options for dry eye sufferers. The acqu…
CareCloud, Inc. announced its Q2 2026 financial results showing 16% revenue growth to $31.9 million and sustained profitability with a GAAP net income of $1.1 million. The company expanded its product portfolio by acquiring Empower Healthcare & Compliance Partners, entering the compliance and audit-defense market. CareCloud reaffirmed its full-year…
GPGI, Inc. announced its Q2 2026 financial results, showing a 4% decrease in pro forma adjusted net sales to $473.2 million and a 13% decline in pro forma adjusted EBITDA to $113.9 million, with margins down 230 basis points. Notably, CompoSecure delivered record performance driven by ROS-enabled improvements, while Husky met expectations amid mark…
The Macerich Company announced its operating partnership's intent to offer $600 million in exchangeable senior notes due 2031 through a private placement targeting qualified institutional buyers. The notes offer semi-annual interest and will be guaranteed by Macerich on a senior unsecured basis. Proceeds will be used to refinance existing secured d…
Ligand Pharmaceuticals reported robust second quarter 2026 financial results with a 32% year-over-year growth in royalty revenue, raising the low end of its adjusted EPS guidance while maintaining revenue guidance. The company completed a $700 million zero-interest convertible debt financing and finalized the acquisition of XOMA Royalty, significan…
Generate Biomedicines Inc. reported continued progress in its clinical programs and platform advancements during Q2 2026. The company is advancing its Phase 3 SOLAIRIA studies for GB-0895 in severe asthma, enrolling patients globally, and will present Phase 1b data for GB-0895 in COPD at the ERS Congress. It also dosed the first cohort in a Phase 1…
Monte Rosa Therapeutics announced robust Q2 2026 results featuring significant clinical and development milestones, including completed enrollment in a key MRT-8102 study targeting cardiovascular disease risk, activation of multiple Phase 2 trials across inflammatory and oncology programs, and a strong financial position with $626 million in cash t…
Avalo Therapeutics reported second quarter 2026 financial results highlighting positive topline Phase 2 results for its lead drug candidate, abdakibart, in hidradenitis suppurativa (HS). The company plans to initiate a registrational Phase 3 clinical program in the first half of 2027 and has expanded its pipeline with AVTX-010, a next-generation an…
Cullinan Therapeutics provided an update on its clinical programs advancing T cell engagers for autoimmune diseases and cancer, highlighting upcoming multi-dose regimen data for CLN-978 and velinotamig, progression to Phase 2 studies in 2027, and a potentially registrational Phase 2 trial for CLN-049 in relapsed/refractory AML starting Q3 2026. The…
Opus Genetics, a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases, announced second quarter 2026 financial results and provided updates on its pipeline. Key milestones include completion of enrollment in the OPGx-LCA5 registrational trial with dosing planned for Q4 2026, upcoming topline data from OP…
Mangoceuticals announced that Nuclea Energy, its merger partner, has signed a non-binding MOU with New Mining Co. to assess the feasibility of deploying Nuclea's advanced modular nuclear reactors to provide behind-the-meter power for New Mining's high-density Bitcoin mining data centers. The phased evaluation could lead to up to 100 MWe capacity, s…
USA Rare Earth, a Nasdaq-listed company focused on rare earth metals and permanent magnets, announced it will release its financial results for Q2 2026 on August 10, followed by a conference call to discuss outcomes and operational progress. The company is advancing its integrated supply chain spanning mining, metal production, and magnet manufactu…
Fiserv, Inc. reported its second quarter 2026 financial results showing a 4% decrease in GAAP revenue and 37% decline in GAAP earnings per share compared to the prior year. Both Merchant Solutions and Financial Solutions segments experienced revenue declines. The company also updated its 2026 organic revenue outlook to a range of -1% to 0% and adju…
Datadog announced its second quarter 2026 financial results with $1.12 billion in revenue, representing 36% year-over-year growth. The company reported positive free cash flow of $279 million and maintained a solid customer base expansion, with approximately 4,720 customers generating over $100k ARR, up 23% from the prior year. Datadog also launche…
Climb Bio, Inc., a clinical-stage biotechnology company focused on immune-mediated diseases, reported its second quarter 2026 financial results and provided updates on key clinical programs. The company highlighted progress in its CLYM116 and budoprutug trials, including upcoming Phase 1 and 2 data presentations and ongoing enrollment. A $110 milli…
Lantheus Holdings, a US-listed radiopharmaceutical company, reported second quarter 2026 revenue of $388.2 million, up 2.7% year-over-year, with adjusted earnings per share slightly down to $1.55. The company announced a definitive agreement for an $8.0 billion all-cash merger with Curium US Holdings LLC, valuing Lantheus shares at $102.50 per shar…
KVH Industries reported a 27% increase in total revenues for Q2 2026 compared to the same quarter last year, driven by a substantial rise in low earth orbit (LEO) service sales primarily from Starlink and OneWeb subscribers. Service revenues grew significantly while product sales saw an 11-12% increase. The company highlights strategic progress in …
Sotera Health Company delivered strong financial performance in Q2 and the first half of 2026, with double-digit increases in net income and Adjusted EBITDA margins. The company raised its full-year 2026 revenue and Adjusted EBITDA growth outlook, driven by solid growth across its three business segments: Sterigenics, Nordion, and Nelson Labs. Impr…
Intellia Therapeutics announced promising Phase 3 clinical trial results for lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR gene editing candidate for hereditary angioedema (HAE), demonstrating significant attack reduction and favorable safety profile. The company expects FDA acceptance of a biologics license application (BLA) in the second hal…
American Shared Hospital Services announced its upcoming Q2 2026 financial results conference call, highlighting continued growth and expansion in stereotactic radiosurgery, Gamma Knife, proton therapy, and advanced radiation cancer treatments. The company collaborates with health systems to share in capital investment and profitability while focus…
Foghorn Therapeutics provided its Q2 2026 update highlighting progress in its clinical-stage programs, including the Phase 1 dose escalation of FHD-909 targeting SMARCA4-mutant NSCLC, advancement of selective EP300 and CBP degrader programs for hematological malignancies and breast cancer, and initiation of a novel oral immunology inflammation prog…
